Erasca to Present at the 8th Annual Evercore Healthcare Conference | ERAS Stock News
Erasca, Inc., a clinical-stage precision oncology company, announced its participation in the 8th Annual Evercore Healthcare Conference on December 3, 2025. The event will include a fireside chat and one-on-one investor meetings, with a live webcast available online. Erasca focuses on therapies for RAS/MAPK pathway-driven cancers, aiming to erase cancer through novel therapies and combination regimens.
SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 8th Annual Evercore Healthcare Conference being held at theLoews Coral Gables Hotel inCoral Gables, FL. Management will participate in a fireside chat onWednesday, December 3, 2025, at10:25 am Eastern Timeand will also participate in one-on-one investor meetings.
A live audio webcast of the event will be available online atErasca.com/events. An archived replay of the event will be available for 30 days following the webcast atErasca.com/events.
About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.
Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
